Rhumbline Advisers grew its holdings in Sientra Inc (NASDAQ:SIEN) by 55.6% during the 2nd quarter, Holdings Channel reports. The firm owned 21,621 shares of the medical instruments supplier’s stock after purchasing an additional 7,725 shares during the period. Rhumbline Advisers’ holdings in Sientra were worth $422,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Commonwealth Equity Services LLC bought a new position in shares of Sientra in the 2nd quarter valued at about $210,000. Barclays PLC boosted its stake in shares of Sientra by 133.7% in the 1st quarter. Barclays PLC now owns 31,521 shares of the medical instruments supplier’s stock valued at $304,000 after purchasing an additional 18,033 shares during the last quarter. First Mercantile Trust Co. bought a new position in shares of Sientra in the 2nd quarter valued at about $427,000. Emerald Advisers Inc. PA bought a new position in shares of Sientra in the 2nd quarter valued at about $527,000. Finally, Columbia Partners L L C Investment Management bought a new position in shares of Sientra in the 2nd quarter valued at about $975,000. 89.21% of the stock is currently owned by institutional investors.

In related news, CEO Jeffrey M. Nugent sold 1,852 shares of Sientra stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $24.90, for a total transaction of $46,114.80. Following the transaction, the chief executive officer now owns 297,999 shares of the company’s stock, valued at approximately $7,420,175.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 31.00% of the stock is owned by company insiders.

Several brokerages have recently issued reports on SIEN. BidaskClub raised shares of Sientra from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 5th. Zacks Investment Research raised shares of Sientra from a “sell” rating to a “hold” rating in a research note on Saturday, September 8th. Dougherty & Co began coverage on shares of Sientra in a research note on Thursday, August 30th. They issued a “buy” rating and a $31.00 target price on the stock. Stephens reaffirmed a “buy” rating and issued a $30.00 target price on shares of Sientra in a research note on Thursday, August 9th. Finally, Stifel Nicolaus raised their target price on shares of Sientra from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. One analyst has rated the stock with a sell rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $22.50.

Sientra stock opened at $24.33 on Friday. Sientra Inc has a fifty-two week low of $8.79 and a fifty-two week high of $26.79. The company has a market cap of $677.72 million, a P/E ratio of -8.63 and a beta of -0.79. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.63 and a current ratio of 3.06.

Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Tuesday, August 7th. The medical instruments supplier reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.04). Sientra had a negative return on equity of 151.47% and a negative net margin of 131.16%. The firm had revenue of $17.55 million for the quarter, compared to the consensus estimate of $15.30 million. analysts expect that Sientra Inc will post -2.93 EPS for the current fiscal year.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Recommended Story: What is Considered a Good Return on Equity (ROE)?

Want to see what other hedge funds are holding SIEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sientra Inc (NASDAQ:SIEN).

Institutional Ownership by Quarter for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.